Abstracts tagged "Lupus nephritis"

Abstract Number: 2895 • 2019 ACR/ARP Annual Meeting
Complement Protein CL-K1 at High Concentrations Protects Against the Development of Lupus Nephritis
Anne Troldborg¹, Anne Voss ², Søren Werner Karlsjov Hansen ³, Jens Christian Jensenius ⁴, Kristian Stengaard-Pedersen ⁵ and Steffen Thiel ⁶, ¹Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Aarhus, Denmark, ²Odense University Hospital, Department of Rheumatology, Odense, Denmark, ³University of Southern Denmark, Odense, Denmark, ⁴Aarhus University, department of biomedicine, Aarhus, Denmark, ⁵Department of Rheumatology, Department of Clinical Medicine, Aarhus University Hospital, Aarhus University, Aarhus, Denmark, Aarhus, Denmark, ⁶Department of Biomedicine, Aarhus University, Aarhus, Denmark, Aarhus, Denmark
Background/Purpose: Nephritis is a severe manifestation of systemic lupus erythematosus (SLE) that develops in 30 to 50 percent of the patients. At the time of…
Abstract Number: 880 • 2019 ACR/ARP Annual Meeting
Diseased Lupus Nephritis Kidneys Serve as a Primary Site of Systemic Autoimmune Development
Matthew Woodruff¹, Christopher Tipton ¹, Jennifer Hom ¹ and Iñaki Sanz ¹, ¹Emory University, Atlanta, GA
Background/Purpose: Lupus nephritis (LN) is an autoimmune destruction of the kidney glomeruli and loss of kidney function affecting almost half of lupus patients. Although the…
Abstract Number: 1930 • 2019 ACR/ARP Annual Meeting
Analysis of Lupus Nephritis Gene Expression Reveals Dysregulation of Pathogenic Pathways Activated Within Infiltrating Cells
Adam Labonte¹, Jackson Xu ², Sarah Heuer ², Robert Robl ², Prathyusha Bachali ¹, Michelle Catalina ¹, Peter Lipsky ³ and Amrie Grammer ⁴, ¹AMPEL Biosolutions and the RILITE Research Institute, Charlottesville, VA, ²AMPEL BioSolutions, Charlottesville, VA, ³AMPEL BioSolutions, LLC, Charlottesville, VA, ⁴AMPEL BioSolutions and RILITE Research Institute, Charlottesville, VA
Background/Purpose: LN is a serious complication of SLE that affects about 20-40% of all lupus patients and leads to kidney damage, end-stage renal disease, and…
Abstract Number: 2896 • 2019 ACR/ARP Annual Meeting
The Role of Alterations in the Splicing Machinery in the Pathogenesis of Lupus: Does It Impact Lupus Nephritis?
Chary Lopez-Pedrera¹, Alejandro Ibañez-Costa ¹, Mª Ángeles Aguirre-Zamorano ², Laura Pérez-Sanchez ³, Alejandra Patiño-Trives ¹, Maria Luque-Tevar ¹, Maria del Carmen Abalos-Aguilera ¹, Ivan Arias de la Rosa ⁴, Nuria Barbarroja ⁵, Mario Espinosa ⁶, Eduardo Collantes-Estevez ⁴, Justo Castaño ⁷, Raúl Luque ⁷ and Carlos Perez-Sanchez ⁸, ¹IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ³MIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁴University of Cordoba/IMIBIC/Reina Sofia Hospital, Cordoba, Spain, ⁵University of Cordoba/IMIBIC/Reina Sofia Hospital and CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain, ⁶UGC de Nefrología. Hospital Universitario Reina Sofía, Cordoba, Spain, ⁷Maimónides Institute for Biomedical Research at Córdoba, Cordoba, Spain, ⁸Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, Cordoba, Spain
Background/Purpose: The aim of this study was to evaluate whether alterations in the splicing machinery of immune cells could influence the development and activity of…
Abstract Number: 882 • 2019 ACR/ARP Annual Meeting
Serum Anti-Vimentin Autoantibodies May Uniquely Predict Response to Therapy in Lupus Nephritis
Andrew Kinloch¹, Matthew Cascino ², Jian Dai ³, Rene Bermea ¹, Kichul Ko ¹, Margaret Vesselits ⁴, Maureen Legendre ⁵, Michael Okoreeh ¹, David Markovitz ⁵, Leonard Dragone ⁶, Michael Townsend ³ and Marcus Clark ¹, ¹University of Chicago, Chicago, IL, ²Genentech, Inc., San Fransisco, CA, ³Genentech, San Fransisco, CA, ⁴University of Chicago, Chicago, ⁵University of Michigan, Ann Arbor, MI, ⁶UCSF, San Fransisco, CA
Background/Purpose: Tubulointerstitial inflammation (TII) in lupus nephritis (LN) is associated with a worse prognosis. Vimentin, a cytoplasmic antigen, is commonly targeted by in situ activated…
Abstract Number: 2046 • 2019 ACR/ARP Annual Meeting
NMR Spectroscopy Reveals Alterations of Urinary Acetate and Citrate Levels Following Cyclophosphamide Therapy in Patients with Lupus Nephritis
Sujata Ganguly¹, Umesh Kumar ², Anupam Guleria ³, Sanjukta Majumder ⁴, Sanat Phatak ¹, Smriti Chaurasia ¹, Nikhil Gupta ⁵, Sandeep Kumar ⁶, Amita Aggarwal ⁷, Dinesh Kumar ³ and Ramnath Misra ⁴, ¹Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Lucknow, India, ²Centre of Biomedical Research SGPGIMS, Raibareli Road, Lucknow-226014, India, Lucknow, Uttar Pradesh, India, ³Centre for Biomedical Research, Sanjay Gandhi Post Graduate Institute of Medical Science, Lucknow, Uttar Pradesh, India, ⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Lucknow, Uttar Pradesh, India, ⁵Centre for Biomedical Research, Lucknow, DELHI, Delhi, India, ⁶Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Post Graduate Institute of Medical Science, Lucknow, Uttar Pradesh, India, ⁷Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India
Background/Purpose: Metabolomics, the study of global alterations in small metabolites is a useful tool to look for novel biomarkers. Recently, we reported a reprogramming of…
Abstract Number: 2898 • 2019 ACR/ARP Annual Meeting
Evaluation of the Transcriptome of Non-Lesional, Non-Sun Exposed Skin in Patients with Lupus Nephritis
Hemant Suryawanshi¹, Robert Clancy ², Evan Der ³, Peter Izmirly ², H Michael Belmont ⁴, Chaim Putterman ⁵, Jill Buyon ² and Thomas Tuschl ¹, ¹Rockefeller Research Laboratories, New York, ²NYU School of Medicine, New York, ³Albert Einstein College of Medicine, New York, ⁴NYU Langone Health, New York, NY, ⁵Albert Einstein College of Medicine, New York, NY
Background/Purpose: The impact of renal injury in lupus nephritis (LN) is widespread with consequences to resident cells in other tissue beds, even non-lesional, non-sun exposed…
Abstract Number: 941 • 2019 ACR/ARP Annual Meeting
Treatment of Lupus Nephritis with anti-CD20 Followed by Anti-BAFF: Impact on B Cell Reconstitution, B Cell Subsets, and Autoreactivity
Yemil Atisha Fregoso¹, Susan Malkiel ², Kristina Harris ³, Sai Kanaparthi ³, Margie Byron ⁴, Linna Ding ⁵, Dawn Smilek ⁶, David Wofsy ⁷, Maria Dall'Era ⁸, Cynthia Aranow ¹ and Betty Diamond ⁹, ¹Feinstein Institute for Medical Research, Manhasset, NY, ²Feinstein Institute for Medical Research, Manhasset, ³Immune Tolerance Network, Bethesda, ⁴Rho Federal Systems, Inc., Chapel Hill, NC, ⁵National Institute of Allergy and Infectious Diseases, Bethesda, MD, ⁶Immune Tolerance Network, San Francisco, CA, ⁷UCSF, San Francisco, ⁸University of California, San Francisco, San Francisco, CA, ⁹Feinstein Institutes for Medical Research, Manhasset
Background/Purpose: Despite the relevance of B cells in lupus, two clinical trials of anti-CD20 failed to meet primary endpoints in patients with lupus and lupus…
Abstract Number: 2116 • 2019 ACR/ARP Annual Meeting
Serious Infection in Patients with Systemic Lupus Erythematosus, Lupus Nephritis and Rheumatoid Arthritis Compared to the General Population: Incidence Rates Using Real-World Claims Data
Lisa Lindsay¹, Ching-Yi Chuo ², Nicholas Jones ², Joshua Galanter ², Anna McGregor ² and Katie Tuckwell ², ¹Genentech Inc, SOUTH SAN FRANCISCO, CA, ²Genentech Inc, SOUTH SAN FRANCISCO
Background/Purpose: Patients with systemic lupus erythematosus (SLE), lupus nephritis (LN) and rheumatoid arthritis (RA) are at risk of serious infections (SIs) due to the impact…
Abstract Number: 2899 • 2019 ACR/ARP Annual Meeting
Transcriptomic Meta-analysis of Lupus Affected Tissues Reveals Shared Immune, Metabolic, and Biochemical Dysregulation
Kathryn Kingsmore¹, Sarah Heuer ¹, Erika Hubbard ¹, Michelle Catalina ², Prathyusha Bachali ², Peter Lipsky ³ and Amrie Grammer ¹, ¹AMPEL BioSolutions and RILITE Research Institute, Charlottesville, VA, ²AMPEL BioSolutions and the RILITE Research Institute, Charlottesville, VA, ³AMPEL BioSolutions, LLC, Charlottesville, VA
Background/Purpose: Systemic lupus erythematosus (SLE) affects various organs and tissues, but whether pathologic processes in each organ are distinct or whether dysregulated molecular functions are…
Abstract Number: 959 • 2019 ACR/ARP Annual Meeting
A Novel Image Analysis Program, “CytoSkaler”, Demonstrates That Anti-Vimentin Antibody Affinity Maturation in Lupus Tubulointerstitial Nephritis Also Results in More Selective Antigen Targeting
Andrew Kinloch¹, Aazam Mohsin ¹, Yuta Asano ¹, Carole Henry ¹, Nirit Mor Vaknin ², Maureen Legendre ², Patrick Wilson ¹, David Markovitz ² and Marcus Clark ¹, ¹University of Chicago, Chicago, IL, ²University of Michigan, Ann Arbor, MI
Background/Purpose: Vimentin is a dominant target of B-cells selected in lupus tubulointerstial inflammation (TII), a predictor of renal failure. The origins of anti-vimentin antibodies (AVA)…
Abstract Number: 2275 • 2019 ACR/ARP Annual Meeting
Effect of Race and Lupus Nephritis on Pregnancy Outcomes in Systemic Lupus Erythematosus: An Individual Participant Meta-analysis
Ravyn Njagu¹, Amanda Eudy ², Stephen Balevic ³, Michelle Petri ⁴, Dafna Gladman ⁵, Murray Urowitz ⁶ and Megan Clowse ², ¹Duke University, Durham, NC, ²Duke University, Durham, ³Duke University, Hillsborough, NC, ⁴Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ⁶University Health Network, University of Toronto, Toronto, ON, Canada
Background/Purpose: Individual cohort studies have found that Black and Hispanic women have worse pregnancy outcomes compared to their white counterparts. Additionally, this population of women…
Abstract Number: 62 • 2019 ACR/ARP Annual Meeting
Human Gingiva-derived Mesenchymal Stem Cells Are Therapeutic in Lupus Nephritis Through Targeting of CD39-CD73 Signaling Pathway
Song Guo Zheng¹, Julie Wang ², Junlong dang ³, Nancy Olsen ⁴ and Wael Jarjour ¹, ¹Ohio State College of Medicine, Columbus, OH, ²Ohio State University, columbus, ³Sun Yat-sen University, Guangzhou, ⁴Penn State University, Hershey, PA
Background/Purpose: Cell specific and cytokine targeted therapeutics have underperformed in systemic lupus erythematosus (SLE) in spite of numerous targets examined and clinical trials conducted. Mesenchymal…
Abstract Number: 1018 • 2019 ACR/ARP Annual Meeting
Renal Single Cell Genomics Links Type II Interferon and Lupus Nephritis in African-Americans
Andrea Fava¹, Yuji Zhang ², Jill Buyon ³, Chaim Putterman ⁴, Nir Hacohen ⁵, Arnon Arazi ⁵, Celine Berthier ⁶, Deepak Rao ⁷, Michael Brenner ⁸, David Wofsy ⁹, Anne Davidson ¹⁰, Mathias Kretzler ¹¹, David Hildeman ¹², E. Steve Woodle ¹², Betty Diamond ¹⁰, Thomas Tuschl ¹³, Evan Der ¹⁴, Hemant Suryawanshi ¹³, H. Michael Belmont ¹⁵, Peter Izmirly ¹⁶, Robert Clancy ¹⁶, The Accelerating Medicines Partnership ¹⁷ and Michelle Petri ¹⁸, ¹Johns Hopkins University, Baltimore, ²University of Maryland, Baltimore, ³NYU School of Medicine, New York, ⁴Albert Einstein College of Medicine, New York, NY, ⁵Broad Institute, Cambridge, ⁶University of Michigan, Ann Arbor, MI, ⁷Brigham and Women's Hospital, Boston, MA, ⁸Brigham and Women’s Hospital:, Boston, ⁹UCSF, San Francisco, ¹⁰Feinstein Institutes for Medical Research, Manhasset, ¹¹University of Michigan, Ann Arbor, ¹²University of Cincinnati, Cincinnati, ¹³Rockefeller Research Laboratories, New York, ¹⁴Albert Einstein College of Medicine, New York, ¹⁵New York University School of Medicine, Ney York, ¹⁶New York University School of Medicine, New York, ¹⁷Multiple Organizations, USA, ¹⁸Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Compared to Caucasian, African-American ethnicity is associated with a higher risk of developing systemic lupus erythematosus, lupus nephritis, high-risk histological features, resistance to treatment,…
Abstract Number: 2528 • 2019 ACR/ARP Annual Meeting
Effect of Additional Administration of HCQ on Pro-inflammatory Cytokine Expression, Especially in Lupus Nephritis
Risa Wakiya¹, Kiyo Ueeda ², Hiromi Shimada ², Shusaku Nakashima ¹, Mai Mahmoud Fahmy Mansour ¹, Mikiya Kato ¹, Taichi Miyagi ¹, Tomohiro Kameda ¹ and Hiroaki Dobashi ², ¹Kagawa University, Kagawa, ²Kagawa University, Kagawa, Japan
Background/Purpose: Hydroxychloroquine(HCQ) is recommended for all patients with SLE in EULAR recommendation 2019, however, there are not enough data about the effect of additional HCQ…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].